Loading
Life sciences · Journal article
Acs Nutrition Science · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed obesity treatment, yet gastrointestinal intolerance, high cost and weight regain after discontinuation highlight the need for complementary strategies. Stimulating endogenous GLP-1 via nutrient-sensing G protein-coupled receptors on enteroendocrine L cells offers a route to modulate satiety pathways. We developed a peptide design platform that couples AlphaFold2-based structural and AI-guided modeling with de novo and pharmacophore-guided design for nutrient-sensing GPCRs, integrated with high-throughput peptide synthesis and in vitro screening. Iterative refinement over four rounds yielded peptides producing >27-fold increases in GLP-1 secretion in STC-1 cells, exceeding the effect of an optimized small-molecule GLP-1 secretagogue in vitro. In diet-induced obese rats, 28 days of oral dosing reduced food intake and body weight with semaglutide as an active comparator. Our work establishes a framework for nutritional ingredient discovery and a blueprint for functional peptides targeting gut hormone systems associated with metabolic health.